RxDoctor Payments Data

Nayeem Karim, DO

Neurology · Hopewell, VANPI 1073690079

Payments from drug & device makers

$29,905in general payments, 2019–2025

Across 75 payments — averaging $398.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$27K
  • Irhythm Technologies, Inc.$379
  • Neurelis, Inc.$364
  • AbbVie$265
  • Livanova USA, Inc.$239
  • Jazz Pharmaceuticals Inc.$193
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$3,91013%
  • Speaking & faculty fees$20,51069%
  • Travel & lodging$1,3104%
  • Food & beverage$4,05514%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,905 in reported general payments places this provider in the 80th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$72,122
Medicare patients
435
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe156$129,784
UbrelvyUbrogepant26$37,323
Nurtec OdtRimegepant Sulfate38$36,565
ValtocoDiazepam11$24,550
QuliptaAtogepant20$21,588
Lamictal XrLamotrigine13$18,258
Emgality PenGalcanezumab-Gnlm17$11,613
DepakoteDivalproex Sodium13$10,809
NamzaricMemantine Hcl/Donepezil Hcl11$9,853
Sumatriptan Succinate131$5,944
Lacosamide31$5,576
TegretolCarbamazepine13$4,606
Memantine Hcl236$4,519
Topiramate182$3,724
Donepezil Hcl296$2,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$265$68,76457 claims
Neurelis, Inc.Valtoco$364$24,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 474 neurology providers in Virginia.

Other neurology in Hopewell

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →